MacroGenics Highlights Progress at 2016 R&D Day
Advancement of HER2 franchise led by margetuximab Expansion and progression of B7-H3 franchise Introduction of PD-1 directed immuno-oncology franchise Clinical updates on multiple DART® studies underscore platform progress Pipeline poised to expand with at …